Lilly terminates ocadusertib license deal with Rigel; effective June 15, 2026

This filing

On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreement”), between Rigel and Lilly.

Comparable filing

Barings BDC, Inc. (the “Company”) and Barings LLC (the “Adviser”) entered into a new Credit Support Agreement (the “New CSA”). The New CSA provides similar credit support as previously provided under the Prior CSA for the remaining unrealized investments in two portfolio companies previously covered by the Prior CSA in an amount equal to the $10,994,928 fair value of such investments as of May 29, 2026 (the “Remaining Obligation”).

This filing

On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreement”), between Rigel and Lilly.

Comparable filing

On May 7, 2026, Serve Robotics Inc. (the “Company”) and each of Cantor Fitzgerald & Co., Wedbush Securities Inc., Northland Securities, Inc., Ladenburg Thalmann & Co. Inc. and Seaport Global Securities LLC (collectively, the “Agents”) agreed to terminate the Controlled Equity Offering SM Agreement, dated as of March 6, 2025 (the “Prior Sales Agreement”).

This filing

On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreement”), between Rigel and Lilly.

Comparable filing

On May 7, 2026, in connection with entering into the Agreement, the Company agreed with Goldman Sachs and Leerink Partners (formerly known as SVB Securities LLC), to terminate that certain Equity Distribution Agreement, dated May 4, 2023, by and among the Company, Goldman Sachs and Leerink Partners, effective as of May 7, 2026.

This filing

On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreement”), between Rigel and Lilly.

Comparable filing

On May 7, 2026, Avai Bio, Inc., formerly known as Avant Technologies Inc. (the “Company” or “AVAI”), and Ainnova Tech Inc. (“Ainnova” or “AINN”) entered into a Mutual Termination Agreement (the “Termination Agreement”) to terminate, by mutual consent, the Joint Venture and License Agreement dated November 8, 2024 (effective as of November 11, 2024) (the “License Agreement”).

This filing

On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreement”), between Rigel and Lilly.

Comparable filing

On May 1, 2026, the Company delivered written notice to Aero terminating the Merger Agreement pursuant to Section 7.1(b) thereof.

This filing

On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreement”), between Rigel and Lilly.

Comparable filing

On April 24, 2026, Ligand Pharmaceuticals Incorporated (the “Company”) delivered written notice to Viking Therapeutics, Inc. (“Viking”) of termination of the TR-Beta Program (the “Termination Notice”) under that certain Master License Agreement, dated May 21, 2014, by and among the Company, Metabasis Therapeutics, Inc. and Viking, as amended by the First Amendment dated September 6, 2014, the Second Amendment dated April 8, 2015, and the Waiver, Consent and Third Amendment dated March 21, 2016 (the “License Agreement”).

This filing

On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreement”), between Rigel and Lilly.

Comparable filing

Effective as of April 30, 2026, ADAC-STRATTEC, LLC (“ADAC-STRATTEC”), a majority owned joint venture subsidiary of Strattec Security Corporation (the “Company”), entered into an Amended and Restated Credit Agreement with BMO Bank N.A. (the “New JV Credit Agreement”) that replaced ADAC-STRATTEC’s existing credit agreement, dated June 28, 2012, with BMO Bank N.A.

This filing

On April 16, 2026, Rigel Pharmaceuticals, Inc. (“Rigel”) received written notice from Eli Lilly and Company (“Lilly”) of Lilly’s election to terminate that certain License and Collaboration Agreement, dated February 18, 2021 (the “Agreement”), between Rigel and Lilly.

Comparable filing

On April 23, 2026, the Company received a written notice (the “Notice”) that ForHumanity intends to terminate and rescind the ForHumanity Agreement, among other matters.